Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study
In AIDS Clinical Trials Group A5202, participants who reported missing their medication within the past month or not providing adherence reports at both 8 and 24 weeks had 5 times the hazard of virological failure compared to more adherent participants. Adherence interventions should focus on such p...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2017-06, Vol.64 (11), p.1612-1614 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1614 |
|---|---|
| container_issue | 11 |
| container_start_page | 1612 |
| container_title | Clinical infectious diseases |
| container_volume | 64 |
| creator | Parker, Robert A. Rabideau, Dustin J. Sax, Paul E. Tierney, Camlin Daar, Eric S. Collier, Ann C. Losina, Elena Freedberg, Kenneth A. |
| description | In AIDS Clinical Trials Group A5202, participants who reported missing their medication within the past month or not providing adherence reports at both 8 and 24 weeks had 5 times the hazard of virological failure compared to more adherent participants. Adherence interventions should focus on such patients. |
| doi_str_mv | 10.1093/cid/cix176 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5434358</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>26374624</jstor_id><sourcerecordid>26374624</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-fbf9adeb2f72d2ec5c848e4f6a2e4131472bcf4a63e2896fcbc185b03ecf99803</originalsourceid><addsrcrecordid>eNpdkctrFTEUxoMotlY37pWAGxFH85xJXAi3xWqhovjahkxy0pvLzOSazIjXv97UW-tjEU5yzo_vfOFD6D4lzyjR_LmLvp7vtGtvoEMqede0UtOb9U6kaoTi6gDdKWVDCKWKyNvogCnONBP8EI1n49a6GaeA34KPzs4xTXjl15BhcoDr40vMaUgX0eFTG4clA46VkIywF3iFP9jJpzH-AP8Uv7d5jnYYdvh4iJP_1VrbApgf44_z4nd30a1ghwL3ruoR-nz66tPJm-b83euzk9V54wRTcxP6oK2HnoWOeQZOOiUUiNBaBoJyKjrWuyBsy4Ep3QbXO6pkTzi4oLUi_Ai93Otul34E72Casx3MNsfR5p1JNpp_J1Ncm4v0zUjBBZeqCjy-Esjp6wJlNmMsDobBTpCWYqhSpLpg9HLXo__QTVryVL9nqCaKE6o6Xakne8rlVEqGcG2GEnOZoqkpmn2KFX74t_1r9HdsFXiwBzZlTvnPvOWdaCvwEwuCok8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1908301879</pqid></control><display><type>article</type><title>Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study</title><source>MEDLINE</source><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Parker, Robert A. ; Rabideau, Dustin J. ; Sax, Paul E. ; Tierney, Camlin ; Daar, Eric S. ; Collier, Ann C. ; Losina, Elena ; Freedberg, Kenneth A.</creator><creatorcontrib>Parker, Robert A. ; Rabideau, Dustin J. ; Sax, Paul E. ; Tierney, Camlin ; Daar, Eric S. ; Collier, Ann C. ; Losina, Elena ; Freedberg, Kenneth A.</creatorcontrib><description>In AIDS Clinical Trials Group A5202, participants who reported missing their medication within the past month or not providing adherence reports at both 8 and 24 weeks had 5 times the hazard of virological failure compared to more adherent participants. Adherence interventions should focus on such patients.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/cix176</identifier><identifier>PMID: 28329243</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Acquired immune deficiency syndrome ; Adhesion ; Adult ; AIDS ; Anti-HIV Agents - administration & dosage ; Anti-HIV Agents - therapeutic use ; BRIEF REPORT ; Clinical trials ; Dideoxynucleosides - administration & dosage ; Dideoxynucleosides - therapeutic use ; Drug Combinations ; Drugs ; Female ; HIV Infections - drug therapy ; HIV-1 - drug effects ; Humans ; Intervention ; Lamivudine - administration & dosage ; Lamivudine - therapeutic use ; Male ; Medical research ; Medication Adherence ; Patient compliance ; Patients ; RNA, Viral - blood ; Self Report ; Tenofovir - administration & dosage ; Tenofovir - therapeutic use ; Treatment Failure ; Viral Load - drug effects ; Virology</subject><ispartof>Clinical infectious diseases, 2017-06, Vol.64 (11), p.1612-1614</ispartof><rights>Copyright © 2017 Oxford University Press on behalf of the Infectious Diseases Society of America</rights><rights>The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.</rights><rights>Copyright Oxford University Press, UK Jun 1, 2017</rights><rights>The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-fbf9adeb2f72d2ec5c848e4f6a2e4131472bcf4a63e2896fcbc185b03ecf99803</citedby><cites>FETCH-LOGICAL-c428t-fbf9adeb2f72d2ec5c848e4f6a2e4131472bcf4a63e2896fcbc185b03ecf99803</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/26374624$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/26374624$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,777,781,800,882,27905,27906,57998,58231</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28329243$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Parker, Robert A.</creatorcontrib><creatorcontrib>Rabideau, Dustin J.</creatorcontrib><creatorcontrib>Sax, Paul E.</creatorcontrib><creatorcontrib>Tierney, Camlin</creatorcontrib><creatorcontrib>Daar, Eric S.</creatorcontrib><creatorcontrib>Collier, Ann C.</creatorcontrib><creatorcontrib>Losina, Elena</creatorcontrib><creatorcontrib>Freedberg, Kenneth A.</creatorcontrib><title>Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>In AIDS Clinical Trials Group A5202, participants who reported missing their medication within the past month or not providing adherence reports at both 8 and 24 weeks had 5 times the hazard of virological failure compared to more adherent participants. Adherence interventions should focus on such patients.</description><subject>Acquired immune deficiency syndrome</subject><subject>Adhesion</subject><subject>Adult</subject><subject>AIDS</subject><subject>Anti-HIV Agents - administration & dosage</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>BRIEF REPORT</subject><subject>Clinical trials</subject><subject>Dideoxynucleosides - administration & dosage</subject><subject>Dideoxynucleosides - therapeutic use</subject><subject>Drug Combinations</subject><subject>Drugs</subject><subject>Female</subject><subject>HIV Infections - drug therapy</subject><subject>HIV-1 - drug effects</subject><subject>Humans</subject><subject>Intervention</subject><subject>Lamivudine - administration & dosage</subject><subject>Lamivudine - therapeutic use</subject><subject>Male</subject><subject>Medical research</subject><subject>Medication Adherence</subject><subject>Patient compliance</subject><subject>Patients</subject><subject>RNA, Viral - blood</subject><subject>Self Report</subject><subject>Tenofovir - administration & dosage</subject><subject>Tenofovir - therapeutic use</subject><subject>Treatment Failure</subject><subject>Viral Load - drug effects</subject><subject>Virology</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkctrFTEUxoMotlY37pWAGxFH85xJXAi3xWqhovjahkxy0pvLzOSazIjXv97UW-tjEU5yzo_vfOFD6D4lzyjR_LmLvp7vtGtvoEMqede0UtOb9U6kaoTi6gDdKWVDCKWKyNvogCnONBP8EI1n49a6GaeA34KPzs4xTXjl15BhcoDr40vMaUgX0eFTG4clA46VkIywF3iFP9jJpzH-AP8Uv7d5jnYYdvh4iJP_1VrbApgf44_z4nd30a1ghwL3ruoR-nz66tPJm-b83euzk9V54wRTcxP6oK2HnoWOeQZOOiUUiNBaBoJyKjrWuyBsy4Ep3QbXO6pkTzi4oLUi_Ai93Otul34E72Casx3MNsfR5p1JNpp_J1Ncm4v0zUjBBZeqCjy-Esjp6wJlNmMsDobBTpCWYqhSpLpg9HLXo__QTVryVL9nqCaKE6o6Xakne8rlVEqGcG2GEnOZoqkpmn2KFX74t_1r9HdsFXiwBzZlTvnPvOWdaCvwEwuCok8</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Parker, Robert A.</creator><creator>Rabideau, Dustin J.</creator><creator>Sax, Paul E.</creator><creator>Tierney, Camlin</creator><creator>Daar, Eric S.</creator><creator>Collier, Ann C.</creator><creator>Losina, Elena</creator><creator>Freedberg, Kenneth A.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170601</creationdate><title>Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study</title><author>Parker, Robert A. ; Rabideau, Dustin J. ; Sax, Paul E. ; Tierney, Camlin ; Daar, Eric S. ; Collier, Ann C. ; Losina, Elena ; Freedberg, Kenneth A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-fbf9adeb2f72d2ec5c848e4f6a2e4131472bcf4a63e2896fcbc185b03ecf99803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adhesion</topic><topic>Adult</topic><topic>AIDS</topic><topic>Anti-HIV Agents - administration & dosage</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>BRIEF REPORT</topic><topic>Clinical trials</topic><topic>Dideoxynucleosides - administration & dosage</topic><topic>Dideoxynucleosides - therapeutic use</topic><topic>Drug Combinations</topic><topic>Drugs</topic><topic>Female</topic><topic>HIV Infections - drug therapy</topic><topic>HIV-1 - drug effects</topic><topic>Humans</topic><topic>Intervention</topic><topic>Lamivudine - administration & dosage</topic><topic>Lamivudine - therapeutic use</topic><topic>Male</topic><topic>Medical research</topic><topic>Medication Adherence</topic><topic>Patient compliance</topic><topic>Patients</topic><topic>RNA, Viral - blood</topic><topic>Self Report</topic><topic>Tenofovir - administration & dosage</topic><topic>Tenofovir - therapeutic use</topic><topic>Treatment Failure</topic><topic>Viral Load - drug effects</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Parker, Robert A.</creatorcontrib><creatorcontrib>Rabideau, Dustin J.</creatorcontrib><creatorcontrib>Sax, Paul E.</creatorcontrib><creatorcontrib>Tierney, Camlin</creatorcontrib><creatorcontrib>Daar, Eric S.</creatorcontrib><creatorcontrib>Collier, Ann C.</creatorcontrib><creatorcontrib>Losina, Elena</creatorcontrib><creatorcontrib>Freedberg, Kenneth A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parker, Robert A.</au><au>Rabideau, Dustin J.</au><au>Sax, Paul E.</au><au>Tierney, Camlin</au><au>Daar, Eric S.</au><au>Collier, Ann C.</au><au>Losina, Elena</au><au>Freedberg, Kenneth A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2017-06-01</date><risdate>2017</risdate><volume>64</volume><issue>11</issue><spage>1612</spage><epage>1614</epage><pages>1612-1614</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>In AIDS Clinical Trials Group A5202, participants who reported missing their medication within the past month or not providing adherence reports at both 8 and 24 weeks had 5 times the hazard of virological failure compared to more adherent participants. Adherence interventions should focus on such patients.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>28329243</pmid><doi>10.1093/cid/cix176</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2017-06, Vol.64 (11), p.1612-1614 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5434358 |
| source | MEDLINE; Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Acquired immune deficiency syndrome Adhesion Adult AIDS Anti-HIV Agents - administration & dosage Anti-HIV Agents - therapeutic use BRIEF REPORT Clinical trials Dideoxynucleosides - administration & dosage Dideoxynucleosides - therapeutic use Drug Combinations Drugs Female HIV Infections - drug therapy HIV-1 - drug effects Humans Intervention Lamivudine - administration & dosage Lamivudine - therapeutic use Male Medical research Medication Adherence Patient compliance Patients RNA, Viral - blood Self Report Tenofovir - administration & dosage Tenofovir - therapeutic use Treatment Failure Viral Load - drug effects Virology |
| title | Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T09%3A04%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Medication%20Adherence%20on%20Virologic%20Failure%20in%20A5202:%20A%20Randomized,%20Partially%20Blinded,%20Phase%203B%20Study&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Parker,%20Robert%20A.&rft.date=2017-06-01&rft.volume=64&rft.issue=11&rft.spage=1612&rft.epage=1614&rft.pages=1612-1614&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/cix176&rft_dat=%3Cjstor_pubme%3E26374624%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1908301879&rft_id=info:pmid/28329243&rft_jstor_id=26374624&rfr_iscdi=true |